20 Results

People

  1. Zelefsky
    Zelefsky
  2. Fair
    Fair
  3. Kantoff
    Kantoff
  4. Morris
    Morris
  5. Reuter
    Reuter
  6. Seshan
    Seshan
  7. Akin
    Akin
  8. Albino
    Albino
  9. Aprikian
    Aprikian
  10. Atoria
    Atoria

Groups

  1. Survivorship Research (8)
  2. Department of Medicine (6)
  3. Genitourinary Oncology Service (6)
  4. Solid Tumor Oncology Division (6)
  5. Epidemiology and Biostatistics (4)
  6. Molecular Pharmacology and Chemistry Program Faculty (4)
  7. Sloan Kettering Institute Faculty (4)
  8. Biostatistics Service (3)
  9. GSK Faculty (3)
  10. Center for Molecular Imaging and Biotechnology (2)
  1. "androgen deprivation"
Formats
  1. Journal Article (16)
  2. Meeting Abstract (2)
  3. Conference Paper (1)
  4. Review (1)
Groups
  1. Survivorship Research (8)
  2. Department of Medicine (6)
  3. Genitourinary Oncology Service (6)
  4. Solid Tumor Oncology Division (6)
  5. Epidemiology and Biostatistics (4)
  6. Molecular Pharmacology and Chemistry Program Faculty (4)

More Groups

People
  1. Michael Zelefsky (7)
  2. William Fair (4)
  3. Michael Morris (2)
  4. Philip Kantoff (2)
  5. Venkatraman Seshan (2)
  6. Victor Reuter (2)

More People

Years
  1. 2023 (1)
  2. 2018 (2)
  3. 2017 (2)
  4. 2014 (1)
  5. 2013 (1)
  6. 2012 (1)

More Years

Publications
  1. Cancer (5)
  2. International Journal of Radiation Oncology, Biology, Physics (3)
  3. Molecular Urology (2)
  4. Urologic Oncology: Seminars and Original Investigations (2)
  5. Clinical and Investigative Medicine (1)
  6. European Urology (1)

More Publications

Publishers
  1. Elsevier Inc. (6)
  2. Wiley Blackwell (5)
  3. Mary Ann Liebert, Inc (2)
  4. American Association for Cancer Research (1)
  5. American College of Cardiology (1)
  6. American Society of Clinical Oncology (1)

More Publishers

Results (20)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Cardiovascular effects of GnRH antagonists compared with agonists in prostate cancer: A systematic review
    Review

    Nelson, A. J.; Lopes, R. D.; Hong, H.; Hua, K.; Slovin, S.; Tan, S.; Nilsson, J.; Bhatt, D. L.; Goodman, S. G.; Evans, C. P.; more...
    JACC: CardioOncology (2023)

    Fulltext@MSK | Save
  • Impact of time to testosterone rebound and comorbidity on the risk of cause-specific mortality in men with unfavorable-risk prostate cancer
    Journal Article

    McDuff, S. G. R.; Chen, M. H.; Renshaw, A. A.; Loffredo, M. J.; Kantoff, P. W.; D'Amico, A. V.
    Cancer (2018)

    Fulltext@MSK | Save
  • Androgen-deprivation therapy, dementia, and cognitive dysfunction in men with prostate cancer: How much smoke and how much fire?
    Journal Article

    McHugh, D. J.; Root, J. C.; Nelson, C. J.; Morris, M. J.
    Cancer (2018)

    Fulltext@MSK | Save
  • Dynamic contrast-enhanced magnetic resonance imaging of prostate cancer: A review of current methods and applications
    Journal Article

    Mazaheri, Y.; Akin, O.; Hricak, H.
    World Journal of Radiology (2017)

    Fulltext@MSK | Save
  • Metastasis-free survival is a strong surrogate of overall survival in localized prostate cancer
    Journal Article

    Xie, W.; Regan, M. M.; Buyse, M.; Halabi, S.; Kantoff, P. W.; Sartor, O.; Soule, H.; Clarke, N. W.; Collette, L.; Dignam, J. J.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Sexual bother in men with advanced prostate cancer undergoing androgen deprivation therapy
    Journal Article

    Benedict, C.; Traeger, L.; Dahn, J. R.; Antoni, M.; Zhou, E. S.; Bustillo, N.; Penedo, F. J.
    Journal of Sexual Medicine (2014)

    Fulltext@MSK | Save
  • A new risk classification system for therapeutic decision making with intermediate-risk prostate cancer patients undergoing dose-escalated external-beam radiation therapy
    Journal Article

    Zumsteg, Z. S.; Spratt, D. E.; Pei, I.; Zhang, Z.; Yamada, Y.; Kollmeier, M.; Zelefsky, M. J.
    European Urology (2013)

    Fulltext@MSK | Save
  • Androgen deprivation and thromboembolic events in men with prostate cancer
    Journal Article

    Ehdaie, B.; Atoria, C. L.; Gupta, A.; Feifer, A.; Lowrance, W. T.; Morris, M. J.; Scardino, P. T.; Eastham, J. A.; Elkin, E. B.
    Cancer (2012)

    Fulltext@MSK | Save
  • Multicenter phase 2 study of neoadjuvant paclitaxel, estramustine phosphate, and carboplatin plus androgen deprivation before radiation therapy in patients with unfavorable-risk localized prostate cancer: Results of Cancer and Leukemia Group B 99811
    Journal Article

    Kelly, W. K.; Halabi, S.; Elfiky, A.; Ou, S. S.; Bogart, J.; Zelefsky, M.; Small, E.
    Cancer (2008)

    Fulltext@MSK | Save
  • Risk-adapted androgen deprivation and escalated three-dimensional conformal radiotherapy for prostate cancer: Does radiation dose influence outcome of patients treated with adjuvant androgen deprivation? A GICOR study. Zapatero A, Valcárcel F, Calvo FA, Algás R, Béjar A, Maldonado J, Villá S, Department of Radiation Oncology, Hospital Universitario de la Princesa, Madrid, Spain
    Journal Article

    Zelefsky, M. J.
    Urologic Oncology: Seminars and Original Investigations (2006)

    Fulltext@MSK | Save